Literature DB >> 18391030

In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years.

Tsi-Shu Huang1, Yung-Ching Liu, Cheng-Len Sy, Yao-Shen Chen, Hui-Zin Tu, Bao-Chen Chen.   

Abstract

Significant increases in the MIC(90)s of linezolid in multidrug-resistant Mycobacterium tuberculosis isolates were seen between the baseline period of 2001 to 2003 (0.5 microg/ml) and 2004 (2 microg/ml). The MICs were 4 microg/ml in three strains. Both fluoroquinolones (except levofloxacin) and kanamycin were found to have statistically significant degrees of concordance with linezolid.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18391030      PMCID： PMC2415800          DOI： 10.1128/AAC.00414-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis.

Authors:  J C Rodríguez; M Ruiz; M López; G Royo
Journal:  Int J Antimicrob Agents       Date:  2002-12       Impact factor: 5.283

2.  In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans.

Authors:  Baohong Ji; Sébastien Lefrançois; Jerome Robert; Aurélie Chauffour; Chantal Truffot; Vincent Jarlier
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

3.  Importance of the efflux pump systems in the resistance of Mycobacterium tuberculosis to fluoroquinolones and linezolid.

Authors:  I Escribano; J C Rodríguez; B Llorca; E García-Pachon; M Ruiz; G Royo
Journal:  Chemotherapy       Date:  2007-10-12       Impact factor: 2.544

4.  Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003.

Authors:  Tsi-Shu Huang; Calvin M Kunin; Susan Shin-Jung Lee; Yao-Shen Chen; Hui-Zin Tu; Yung-Ching Liu
Journal:  J Antimicrob Chemother       Date:  2005-10-04       Impact factor: 5.790

Review 5.  Mycobacterium tuberculosis in Taiwan.

Authors:  Po-Ren Hsueh; Yung-Ching Liu; Jen So; Cheng-Yi Liu; Pan-Chyr Yang; Kwen-Tay Luh
Journal:  J Infect       Date:  2005-10-10       Impact factor: 6.072

6.  First linezolid-resistant clinical isolates of Mycobacterium tuberculosis.

Authors:  Elvira Richter; Sabine Rüsch-Gerdes; Doris Hillemann
Journal:  Antimicrob Agents Chemother       Date:  2007-01-22       Impact factor: 5.191

7.  In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs.

Authors:  Luis Alcalá; María Jesús Ruiz-Serrano; Cristina Pérez-Fernández Turégano; Darío García De Viedma; Marisol Díaz-Infantes; Mercedes Marín-Arriaza; Emilio Bouza
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

Review 8.  Linezolid: the first oxazolidinone antimicrobial.

Authors:  Robert C Moellering
Journal:  Ann Intern Med       Date:  2003-01-21       Impact factor: 25.391
  8 in total
  13 in total

1.  In Vitro Drug Susceptibility of Bedaquiline, Delamanid, Linezolid, Clofazimine, Moxifloxacin, and Gatifloxacin against Extensively Drug-Resistant Tuberculosis in Beijing, China.

Authors:  Yu Pang; Zhaojing Zong; Fengmin Huo; Wei Jing; Yifeng Ma; Lingling Dong; Yunxu Li; Liping Zhao; Yuhong Fu; Hairong Huang
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

Review 2.  Epidemiology and treatment of multidrug resistant tuberculosis.

Authors:  Carole D Mitnick; Sasha C Appleton; Sonya S Shin
Journal:  Semin Respir Crit Care Med       Date:  2008-09-22       Impact factor: 3.119

3.  Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis.

Authors:  Reynaldo Dietze; David Jamil Hadad; Bryan McGee; Lucilia Pereira Dutra Molino; Ethel Leonor Noia Maciel; Charles A Peloquin; Denise F Johnson; Sara M Debanne; Kathleen Eisenach; W Henry Boom; Moises Palaci; John L Johnson
Journal:  Am J Respir Crit Care Med       Date:  2008-09-11       Impact factor: 21.405

Review 4.  WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis.

Authors:  Kwok-Chiu Chang; Wing-Wai Yew; Cheuk-Ming Tam; Chi-Chiu Leung
Journal:  Antimicrob Agents Chemother       Date:  2013-06-17       Impact factor: 5.191

5.  Susceptibility testing of extensively drug-resistant and pre-extensively drug-resistant Mycobacterium tuberculosis against levofloxacin, linezolid, and amoxicillin-clavulanate.

Authors:  Imran Ahmed; Kauser Jabeen; Raunaq Inayat; Rumina Hasan
Journal:  Antimicrob Agents Chemother       Date:  2013-03-18       Impact factor: 5.191

6.  Mycobacterium tuberculosis Mutations Associated with Reduced Susceptibility to Linezolid.

Authors:  Shuo Zhang; Jiazhen Chen; Peng Cui; Wanliang Shi; Xiaohong Shi; Hongxia Niu; Denise Chan; Wing Wai Yew; Wenhong Zhang; Ying Zhang
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

7.  In vitro and in vivo activities of three oxazolidinones against nonreplicating Mycobacterium tuberculosis.

Authors:  Ming Zhang; Claudia Sala; Neeraj Dhar; Anthony Vocat; Vasan K Sambandamurthy; Sreevalli Sharma; Gwendolyn Marriner; V Balasubramanian; Stewart T Cole
Journal:  Antimicrob Agents Chemother       Date:  2014-03-24       Impact factor: 5.191

8.  Linezolid for drug-resistant pulmonary tuberculosis.

Authors:  Bhagteshwar Singh; Derek Cocker; Hannah Ryan; Derek J Sloan
Journal:  Cochrane Database Syst Rev       Date:  2019-03-20

9.  Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.

Authors:  Jeong Seong Yang; Kyung Jong Kim; Hongjo Choi; Seung Heon Lee
Journal:  Ann Lab Med       Date:  2018-11       Impact factor: 3.464

Review 10.  Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations?

Authors:  Wing Wai Yew; Won-Jung Koh
Journal:  Korean J Intern Med       Date:  2015-12-28       Impact factor: 2.884
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.